AMSTERDAM — The European Medicines Agency expects to decide on whether four more coronavirus vaccines, including ones made by China and Russia, should be recommended for authorization across Europe by the end of the year.
Dr. Marco Cavaleri, the agency’s head of vaccines strategy, says the regulator was currently reviewing results of the vaccines made by CureVac and Novavax. The agency officials plan to discuss the shots with both companies “in the coming weeks.”
Earlier this year, CureVac reported its vaccine was less than 50% effective, while Novavax said its shot was about 90% effective. Novavax said it would seek approval first in developing countries rather than focus on the EU or the U.S. markets.
Cavaleri says talks with the Chinese and Russian producers of vaccines had been “constructive,” but more data are needed.